Lasertec International Secures Major Financing
ATLANTA, Ga., March 30 -- Lasertec International, Inc. has secured a financing commitment of $40 million from Lilly Beter Capital Group, Ltd. The Company says the money will fund new product rollout and offset the expense of the Federal Drug Administration approval process of laser-based cancer diagnostic and treatment devices. Lasertec has patented a dye laser system called the Photo Therapy Resonance System to destroy cancer cells without damaging surrounding healthy tissue.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024